Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Acer Therapeutics stock price, quote, forecast and news

ACER
US00444P1084
A2DYQV

Price

0.66
Today +/-
+0
Today %
+0 %
P

Acer Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Acer Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Acer Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Acer Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Acer Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Acer Therapeutics Stock Price History

DateAcer Therapeutics Price
11/20/20230.66 undefined
11/17/20230.80 undefined

Acer Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Acer Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Acer Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Acer Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Acer Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Acer Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Acer Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Acer Therapeutics’s growth potential.

Acer Therapeutics Revenue, EBIT and net profit per share

DateAcer Therapeutics RevenueAcer Therapeutics EBITAcer Therapeutics Net Income
2028e188.61 M undefined136.5 M undefined0 undefined
2027e173.65 M undefined124.16 M undefined0 undefined
2026e150.89 M undefined104.75 M undefined7.4 M undefined
2025e112.14 M undefined70.62 M undefined18.71 M undefined
2024e49.4 M undefined16.36 M undefined2.99 M undefined
2023e8.84 M undefined-15.09 M undefined-18.09 M undefined
20220 undefined-24.61 M undefined-26.24 M undefined
20211.26 M undefined-15.95 M undefined-15.37 M undefined
20200 undefined-22.8 M undefined-22.89 M undefined
20190 undefined-29.9 M undefined-29.42 M undefined
20180 undefined-21.71 M undefined-21.28 M undefined
20170 undefined-13.95 M undefined-14.19 M undefined
20162.91 M undefined-6.95 M undefined-7.98 M undefined
20152.56 M undefined-12.09 M undefined-12.02 M undefined
20141.27 M undefined-15.07 M undefined-15.05 M undefined
20131.27 M undefined-11.92 M undefined-16.66 M undefined
20120 undefined-9.13 M undefined-8.93 M undefined
20110 undefined-5.96 M undefined-5.97 M undefined
20100 undefined-4.97 M undefined-5.47 M undefined
20090 undefined-4.35 M undefined-1.43 M undefined
20080 undefined-11.97 M undefined-11.85 M undefined
20070 undefined-16.72 M undefined-14.67 M undefined
20060 undefined-13.49 M undefined-12.65 M undefined
20050 undefined-11.52 M undefined-14.86 M undefined
20040 undefined-3.3 M undefined-4.62 M undefined
20030 undefined-80,000 undefined-130,000 undefined

Acer Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
00000000001122000010849112150173188
------------100.00--------512.50128.5733.9315.338.67
------------------100.00-------
0000000000000000001,0000000000
0-3-11-13-16-11-4-4-5-9-11-15-12-6-13-21-29-22-15-24-151670104124136
-----------1,100.00-1,500.00-600.00-300.00-----1,500.00--187.5032.6562.5069.3371.6872.34
0-4-14-12-14-11-1-5-5-8-16-15-12-7-14-21-29-22-15-26-18218700
--250.00-14.2916.67-21.43-90.91400.00-60.00100.00-6.25-20.00-41.67100.0050.0038.10-24.14-31.8273.33-30.77-111.11800.00-61.11--
0000.020.020.030.040.050.070.070.160.340.570.687.58.5610.0911.1214.2715.77000000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Acer Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Acer Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
                                       
00.852.5614.972.651.248.183.817.110.5923.649.9112.581.8315.6441.6712.085.7612.712.33
00000000000000000050
00000000000000000000
000000000600670000000000
00.090.180.470.360.090.190.090.120.470.450.760.50.540.881.080.810.6810.381.19
00.942.7415.443.011.338.373.97.231.6624.7610.6713.082.3716.5242.7512.896.4428.093.52
00.340.481.361.371.170.950.821.031.271.31.10.840.010.060.130.790.530.110.41
00000000000000000000
00000000000000000050
026.7926.1300000000000.120.120.120.12000
00000000000000.277.657.657.657.657.657.65
000.390000001.210.180.040.500.010.020.0200.410.05
027.13271.361.371.170.950.821.032.481.481.141.340.47.847.928.588.1813.178.11
028.0729.7416.84.382.59.324.728.264.1426.2411.8114.422.7724.3650.6721.4714.6241.2611.62
                                       
00.51.033.353.356.120.150.180.230.060.280.280.0712.140.0700000
0.0627.4439.7863.1276.584.9396.4698.5107.65112.43146.57148.48162.881.1747.8191.9194.62107.36112.78123.98
-0.13-4.75-20.26-59.04-77.71-89.57-89.24-94.71-100.68-109.61-126.27-141.32-153.34-11.36-25.55-46.83-76.25-99.14-114.51-140.75
00000000000000000000
00000000000000000000
-0.0723.1920.557.432.141.487.373.977.22.8820.587.449.611.9522.3345.0818.378.22-1.72-16.76
01.190.690.870.990.650.630.370.490.410.70.70.740.380.11.030.561.671.413.81
0.010.230.240.141.020.20.140.340.580.471.231.21.010.441.834.442.063.872.443.68
00.376.766.770000001.41.233.0500.110.10.150.625.269.13
0.063.091.51.50000000000000000
0000.010.060.060.070.04000000000002.33
0.074.889.199.292.070.910.840.751.070.883.333.134.80.822.045.572.776.1429.1118.95
0000.10.160.11.02000.380000000009.29
00000000000000000000
0000000.090002.341.2300000.330.248.870.15
0000.10.160.11.11000.382.341.2300000.330.248.879.43
0.074.889.199.392.231.011.950.751.071.265.674.364.80.822.045.573.16.3837.9828.39
-028.0729.7416.824.372.499.324.728.274.1426.2511.814.412.7724.3750.6521.4714.636.2611.62
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Acer Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Acer Therapeutics's financial health and stability.

Assets

Acer Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Acer Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Acer Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Acer Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
0-4-14-12-14-11-1-5-5-8-16-15-12-7-14-21-29-22-15-26
00000000000000000000
00000000000000000000
000-3400000400-303-2313-7
02841111005101012213
00000000000000000000
00000000000000000000
0-2-6-11-9-100-4-4-8-6-14-10-9-14-16-29-170-30
00000000000000000000
000000000-10000000000
000000000-1,0001,0000001,00000000
00000000000000000000
032000100400005000411
00521095080280130214201038
038210960832801302642010720
--------------------
00000000000000000000
0019-9-16-43-623-132-91326-29-66-10
-0.08-2.54-6.48-11.81-9.49-10.6-0.01-4.42-5.29-9.47-6.39-14.39-10.42-9.2-14.16-16.69-29.69-17.04-0.19-30.42
00000000000000000000

Acer Therapeutics stock margins

The Acer Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acer Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acer Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Acer Therapeutics's sales revenue. A higher gross margin percentage indicates that the Acer Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Acer Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Acer Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Acer Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Acer Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Acer Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Acer Therapeutics Margin History

Acer Therapeutics Gross marginAcer Therapeutics Profit marginAcer Therapeutics EBIT marginAcer Therapeutics Profit margin
2028e100 %72.37 %0 %
2027e100 %71.5 %0 %
2026e100 %69.42 %4.9 %
2025e100 %62.97 %16.69 %
2024e100 %33.12 %6.06 %
2023e100 %-170.64 %-204.52 %
2022100 %0 %0 %
2021100 %-1,265.75 %-1,220.16 %
2020100 %0 %0 %
2019100 %0 %0 %
2018100 %0 %0 %
2017100 %0 %0 %
2016100 %-238.83 %-274.23 %
2015100 %-472.27 %-469.53 %
2014100 %-1,186.61 %-1,185.04 %
2013100 %-938.58 %-1,311.81 %
2012100 %0 %0 %
2011100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %
2004100 %0 %0 %
2003100 %0 %0 %

Acer Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Acer Therapeutics earnings per share therefore indicates how much revenue Acer Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Acer Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Acer Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Acer Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Acer Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Acer Therapeutics Revenue, EBIT and net profit per share

DateAcer Therapeutics Sales per ShareAcer Therapeutics EBIT per shareAcer Therapeutics Earnings per Share
2028e7.71 undefined0 undefined0 undefined
2027e7.1 undefined0 undefined0 undefined
2026e6.17 undefined0 undefined0.3 undefined
2025e4.58 undefined0 undefined0.77 undefined
2024e2.02 undefined0 undefined0.12 undefined
2023e0.36 undefined0 undefined-0.74 undefined
20220 undefined-1.56 undefined-1.66 undefined
20210.09 undefined-1.12 undefined-1.08 undefined
20200 undefined-2.05 undefined-2.06 undefined
20190 undefined-2.96 undefined-2.92 undefined
20180 undefined-2.54 undefined-2.49 undefined
20170 undefined-1.86 undefined-1.89 undefined
20164.28 undefined-10.22 undefined-11.74 undefined
20154.49 undefined-21.21 undefined-21.09 undefined
20143.74 undefined-44.32 undefined-44.26 undefined
20137.94 undefined-74.5 undefined-104.13 undefined
20120 undefined-130.43 undefined-127.57 undefined
20110 undefined-85.14 undefined-85.29 undefined
20100 undefined-99.4 undefined-109.4 undefined
20090 undefined-108.75 undefined-35.75 undefined
20080 undefined-399 undefined-395 undefined
20070 undefined-836 undefined-733.5 undefined
20060 undefined-674.5 undefined-632.5 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

Acer Therapeutics business model

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel drugs for rare and life-threatening diseases. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. The history of Acer Therapeutics began with an innovative strategy for rediscovering already approved drugs for new therapeutic applications. The company utilizes a "repurposing" technology, in which already approved drugs are reevaluated and further developed for the treatment of rare diseases. Acer Therapeutics' business model includes a combination of in-house research activities, strategic partnerships, and acquisitions. The company follows a portfolio strategy with a focus on rare diseases to develop a diversified pipeline of innovative medications. The various divisions of Acer Therapeutics focus on different therapeutic areas. Currently, the company is focused on the development of drugs for the treatment of rare anemia, severe lymphocytic leukemia, and narcolepsy. Acer Therapeutics' flagship product is EDSIVO, a medication for the treatment of arterial hypertension, a rare and life-threatening condition characterized by elevated blood pressure in the arteries. EDSIVO is currently approved in the United States and is under review in Europe. The company plans to further develop EDSIVO for the treatment of other rare diseases. Another important product of Acer Therapeutics is ACER-001, a medication for the treatment of the rare metabolic disorder urea cycle disorders. ACER-001 is an oral formulation of sodium phenylbutyrate and is intended to help patients regulate ammonia metabolism and alleviate symptoms. In recent years, Acer Therapeutics has also entered into several strategic partnerships and acquisitions to expand and strengthen its pipeline of rare diseases. In 2019, the company acquired biopharmaceutical specialist Celipheon, thereby expanding its portfolio to include drugs for the treatment of anemia and leukemia. Another important partner of Acer Therapeutics is Ultragenyx Pharmaceutical, a biopharmaceutical company specializing in the development of therapies for rare and ultra-rare diseases. The two companies have entered into a licensing agreement for ACER-001, in which Ultragenyx has exclusive rights for the commercialization of the medication in North America and Europe. Overall, Acer Therapeutics' business model and portfolio strategy have made it a key player in the rare disease sector. Through partnerships and acquisitions, it has expanded its pipeline and focused its research on various therapeutic areas. The company is currently in a growth phase and has the potential to bring more groundbreaking medications for rare diseases to the market in the future. Acer Therapeutics is one of the most popular companies on Eulerpool.com.

Acer Therapeutics SWOT Analysis

Strengths

Acer Therapeutics Inc has developed a unique and innovative product portfolio that sets them apart from competitors in the pharmaceutical industry. Their products offer novel and effective treatments for various medical conditions, providing a competitive advantage.

Acer Therapeutics Inc has a dedicated team of highly skilled researchers and scientists, enabling them to conduct cutting-edge research and develop high-quality pharmaceutical products. This strength enhances their ability to innovate and stay ahead of market trends.

Weaknesses

Acer Therapeutics Inc currently has a limited market presence, impacting their brand recognition and ability to reach a wider customer base. This weakness may hinder their growth potential and market competitiveness in comparison to larger pharmaceutical companies.

Acer Therapeutics Inc relies on strategic partnerships and collaborations with third-party organizations for various aspects, such as manufacturing, distribution, and marketing. Any issues or challenges faced by these partners may have a negative impact on Acer's operations and overall performance.

Opportunities

The market demand for innovative pharmaceutical solutions is increasing as healthcare systems strive to improve patient outcomes. Acer Therapeutics Inc can capitalize on this opportunity by leveraging their unique product portfolio and positioning themselves as a reliable provider of effective treatments.

Acer Therapeutics Inc can explore opportunities to expand their market presence by entering new geographical regions or targeting different therapeutic areas. This expansion can help them diversify their revenue streams and reduce dependence on a single market segment.

Threats

The pharmaceutical industry is subject to strict regulations and compliance requirements. Acer Therapeutics Inc may face challenges in obtaining necessary approvals and licenses for their products, leading to delays in product launches or increased costs for compliance measures.

Acer Therapeutics Inc operates in a highly competitive industry with numerous established players. Competitors may offer similar products or develop alternative treatments, posing a threat to Acer's market share and profitability. Continuous innovation and differentiation are essential to withstand this competitive pressure.

Acer Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Acer Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Acer Therapeutics shares outstanding

The number of shares was Acer Therapeutics in 2023 — This indicates how many shares 15.767 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Acer Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Acer Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Acer Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Acer Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Acer Therapeutics Stock splits

In Acer Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Acer Therapeutics.

Acer Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.26 -0.33  (-26.87 %)2023 Q2
3/31/2023-0.29 -0.77  (-164.88 %)2023 Q1
12/31/2022-0.38 -0.54  (-43.08 %)2022 Q4
9/30/2022-0.7 -0.31  (55.52 %)2022 Q3
6/30/2022-0.58 -0.17  (70.76 %)2022 Q2
3/31/2022-0.42 -0.64  (-51.19 %)2022 Q1
12/31/2021-0.01 -0.31  (-2,939.22 %)2021 Q4
9/30/2021-0.29 -0.23  (19.47 %)2021 Q3
6/30/2021-0.37 -0.23  (37.11 %)2021 Q2
3/31/2021-0.45 -0.11  (75.36 %)2021 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Acer Therapeutics stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

61

👫 Social

66

🏛️ Governance

54

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Acer Therapeutics list of shareholders

%
Name
Stocks
Change
Date
4.64602 % Nantahala Capital Management, LLC1,136,416-66,7106/30/2023
11.08965 % Schelling (Christopher)2,712,52909/25/2023
10.92522 % TVM Capital GmbH2,672,31013/24/2023
1.97768 % Aselage (Stephen J)483,74109/25/2023
1.69691 % The Vanguard Group, Inc.415,06506/30/2023
1.12142 % Hudson Bay Capital Management LP274,300274,3006/30/2023
0.53064 % Anson Funds Management LP.129,79506/30/2023
0.51104 % Palmin (Harry S)125,00009/25/2023
0.41926 % Renaissance Technologies LLC102,552-9,2486/30/2023
0.39383 % Geode Capital Management, L.L.C.96,33006/30/2023
1
2
3
4
5
...
6

Acer Therapeutics Executives and Management Board

Mr. Chris Schelling47
Acer Therapeutics President, Chief Executive Officer, Director (since 2017)
Compensation 834,280
Dr. Adrian Quartel56
Acer Therapeutics Chief Medical Officer
Compensation 801,044
Mr. Jefferson Davis56
Acer Therapeutics Chief Business Officer
Compensation 634,797
Mr. Harry Palmin53
Acer Therapeutics Chief Financial Officer
Compensation 592,593
Mr. Donald Joseph69
Acer Therapeutics Chief Legal Officer, Secretary
Compensation 490,280
1
2
3

Acer Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
RELIEF THERAPEUTICS Holding Stock
RELIEF THERAPEUTICS Holding
SupplierCustomer0,120,730,680,010,550,36
Sanofi Stock
Sanofi
SupplierCustomer-0,13-0,01-0,660,14-0,19-0,30
1

Most common questions regarding Acer Therapeutics

What values and corporate philosophy does Acer Therapeutics represent?

Acer Therapeutics Inc represents a commitment to developing innovative therapeutics to address unmet medical needs. The company's corporate philosophy centers around providing effective treatment options for patients who may have limited or no approved therapies available. Acer aims to prioritize patient health and well-being through rigorous research, clinical development, and regulatory processes. By leveraging its expertise and resources, Acer strives to make a positive impact on the lives of individuals with rare diseases and other serious medical conditions. Through its dedication to scientific innovation and patient-centric approach, Acer Therapeutics Inc aims to improve global healthcare outcomes.

In which countries and regions is Acer Therapeutics primarily present?

Acer Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Acer Therapeutics achieved?

Acer Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully received U.S. Food and Drug Administration (FDA) Fast Track designation for its flagship product, Edsivo™, for the treatment of vEDS, a life-threatening genetic disorder. Additionally, Acer Therapeutics Inc completed a successful Phase 2 clinical trial for Edsivo™, demonstrating its potential in treating vEDS patients. The company also obtained Orphan Drug designation from the FDA for ACER-001, a fully taste-masked and immediate-release formulation of sodium phenylbutyrate, intended to treat patients with urea cycle disorders. Acer Therapeutics Inc's milestones highlight their commitment to innovation and addressing unmet medical needs in rare diseases.

What is the history and background of the company Acer Therapeutics?

Acer Therapeutics Inc. is a pharmaceutical company with a rich history and background. Founded in 2017, Acer is dedicated to developing and commercializing innovative therapies for rare and life-threatening diseases. The company focuses on creating treatments for serious conditions, including vascular Ehlers-Danlos syndrome (vEDS) and maple syrup urine disease (MSUD), among others. With a strong commitment to patient care, Acer Therapeutics strives to make a positive impact on the lives of individuals suffering from these rare diseases. Its research and development efforts underscore the company's mission to improve treatment options and enhance the quality of life for affected patients.

Who are the main competitors of Acer Therapeutics in the market?

The main competitors of Acer Therapeutics Inc in the market include companies such as BioMarin Pharmaceutical Inc, Strongbridge Biopharma plc, and Ultragenyx Pharmaceutical Inc.

In which industries is Acer Therapeutics primarily active?

Acer Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Acer Therapeutics?

The business model of Acer Therapeutics Inc revolves around the development and commercialization of innovative therapies for rare and life-threatening diseases. As a pharmaceutical company, Acer focuses on identifying and advancing potential treatments to address unmet medical needs. By conducting rigorous research and clinical trials, Acer aims to bring novel therapies to patients who may have limited treatment options. This includes leveraging partnerships, collaborations, and strategic acquisitions to expand their pipeline and accelerate the development process. Ultimately, Acer Therapeutics Inc strives to improve the quality of life for individuals affected by rare diseases through the delivery of effective and accessible treatment solutions.

What is the P/E ratio of Acer Therapeutics 2024?

The Acer Therapeutics P/E ratio is 3.48.

What is the P/S ratio of Acer Therapeutics 2024?

The Acer Therapeutics P/S ratio is 0.21.

What is the AlleAktien quality score of Acer Therapeutics?

The AlleAktien quality score for Acer Therapeutics is 5/10.

What is the revenue of Acer Therapeutics 2024?

The expected Acer Therapeutics revenue is 49.4 M USD.

How high is the profit of Acer Therapeutics 2024?

The expected Acer Therapeutics profit is 2.99 M USD.

What is the business model of Acer Therapeutics

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. It is headquartered in Cambridge, Massachusetts and was founded in 2017. The business model of Acer Therapeutics is based on the identification, development, and marketing of drugs for the treatment of rare diseases. The company focuses on diseases that currently have no effective treatment options and utilizes innovative technologies based on advanced scientific knowledge. Acer Therapeutics' portfolio includes various product candidates in different stages of development. One of the key products is the drug Edsivo, developed for the treatment of Vascular Ehlers-Danlos Syndrome (vEDS). vEDS is a rare connective tissue disorder that can lead to life-threatening vascular complications and has had no specific therapies available until now. Edsivo is currently in Phase III of clinical development and has been granted "Breakthrough Therapy" status by the US Food and Drug Administration (FDA), which allows for accelerated approval. Another product of Acer Therapeutics is ACER-001, developed for the treatment of Urea Cycle Disorders, a group of genetic disorders that result in a deficiency of enzymes necessary for ammonia metabolism in the body. ACER-001 is currently in Phase II of clinical development and has been granted "Orphan Drug" status by the FDA, which provides special advantages in market approval. Additional product candidates of Acer Therapeutics are ACER-801, being developed for the treatment of Phenylketonuria, and ACER-2820, which could be suitable for the treatment of Niemann-Pick Disease Type C. Both products are still in preclinical development. The business model of Acer Therapeutics is to successfully develop and bring these products to market, utilizing a combination of internal development activities and strategic partnerships with other companies and research institutions. Acer Therapeutics has already entered into several collaborations with renowned partners to accelerate and optimize the development of its product candidates. Acer Therapeutics finances its activities through a combination of equity financing and debt financing. Since its inception, the company has conducted multiple successful financing rounds, raising several million US dollars in total. In summary, Acer Therapeutics' business model is focused on developing and bringing innovative therapies for rare diseases to market. The company relies on innovative technologies, strategic partnerships, and sustainable financing. With its portfolio of promising product candidates, Acer Therapeutics has the potential to significantly impact the rare disease market and improve the lives of millions of people.

What is the Acer Therapeutics dividend?

Acer Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Acer Therapeutics pay dividends?

The dividend cannot currently be calculated for Acer Therapeutics or the company does not pay out a dividend.

What is the Acer Therapeutics ISIN?

The ISIN of Acer Therapeutics is US00444P1084.

What is the Acer Therapeutics WKN?

The WKN of Acer Therapeutics is A2DYQV.

What is the Acer Therapeutics ticker?

The ticker of Acer Therapeutics is ACER.

How much dividend does Acer Therapeutics pay?

Over the past 12 months, Acer Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acer Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acer Therapeutics?

The current dividend yield of Acer Therapeutics is .

When does Acer Therapeutics pay dividends?

Acer Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acer Therapeutics?

Acer Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acer Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acer Therapeutics located?

Acer Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acer Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acer Therapeutics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Acer Therapeutics pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Acer Therapeutics in the year 2023?

In the year 2023, Acer Therapeutics distributed 0 USD as dividends.

In which currency does Acer Therapeutics pay out the dividend?

The dividends of Acer Therapeutics are distributed in USD.

All fundamentals about Acer Therapeutics

Our stock analysis for Acer Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acer Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.